id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-5767-0029,FDA,FDA-2017-D-5767,ANDAs for Certain Highly  Purified Synthetic Peptide  Drug Products That Refer to  Listed Drugs of rDNA  Origin Guidance for Industry,Other,Guidance,2021-05-20T04:00:00Z,2021,5,2021-05-20T04:00:00Z,,2024-11-06T23:47:57Z,,1,0,0900006484b23f31
FDA-2017-D-5767-0028,FDA,FDA-2017-D-5767,"Abbreviated New Drug Applications for Certain Highly Purified Synthetic Peptide Drug Products That Refer to 
Listed Drugs of Recombinant Deoxyribonucleic Acid; Guidance for Industry; Availability",Notice,Notice of Availability,2021-05-20T04:00:00Z,2021,5,2021-05-20T04:00:00Z,,2021-05-25T13:29:16Z,2021-10603,0,0,0900006484b235e6
FDA-2017-D-5767-0021,FDA,FDA-2017-D-5767,"Abbreviated New Drug Applications for Certain Highly Purified Synthetic
Peptide Drug Products That Refer to Listed Drugs of Recombinant
Deoxyribonucleic Acid Origin; Draft Guidance for Industry; Availability;
Extension of Comment Period",Notice,Notice of Availability,2017-12-08T05:00:00Z,2017,12,2017-12-08T05:00:00Z,2018-02-05T04:59:59Z,2018-02-03T02:04:56Z,2017-26436,0,0,0900006482cf2a7a
FDA-2017-D-5767-0022,FDA,FDA-2017-D-5767,ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin Guidance for Industry DRAFT GUIDANCE,Other,Guidance,2017-12-08T05:00:00Z,2017,12,2017-12-08T05:00:00Z,2018-02-05T04:59:59Z,2019-06-18T16:11:51Z,,0,0,0900006482cf3aff
FDA-2017-D-5767-0016,FDA,FDA-2017-D-5767,Request for Extension for United States Pharmacopeia (USP),Other,Request for Extension,2017-12-04T05:00:00Z,2017,12,2017-10-03T04:00:00Z,2017-12-05T04:59:59Z,2017-12-04T21:56:11Z,,0,0,0900006482cd6122
FDA-2017-D-5767-0001,FDA,FDA-2017-D-5767,"Abbreviated New Drug Applications for Certain Highly Purified Synthetic
Peptide Drug Products That Refer to Listed Drugs of Recombinant
Deoxyribonucleic Acid Origin; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2017-10-03T04:00:00Z,2017,10,2017-10-03T04:00:00Z,2017-12-05T04:59:59Z,2017-12-05T02:04:00Z,2017-21202,0,0,0900006482b9376f
FDA-2017-D-5767-0002,FDA,FDA-2017-D-5767,ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin Guidance for Industry DRAFT GUIDANCE,Other,Guidance,2017-10-03T04:00:00Z,2017,10,2017-10-03T04:00:00Z,2017-12-05T04:59:59Z,2024-11-07T01:17:03Z,,1,0,0900006482b94e60